Condition: Ulcerative Colitis · Sponsor: Gilead Sciences
The goal of this study is to learn if tilpisertib fosmecarbil (formerly known as GS-5290) is effective and safe in treating participants with moderate to severe ulcerative colitis. The study will compare participants in different treatment groups treated with tilpisertib fosmecarbil with participants treated with placebo. The primary objective of this study is to demonstrate the efficacy of tilpisertib fosmecarbil, compared to placebo control, in achieving Clinical Response at Week 12.
This description comes directly from the study's public registry record.
Gilead Clinical Study Information Center · 1-833-445-3230 (GILEAD-0) · GileadClinicalTrials@gilead.com
Always discuss trial participation with your own doctor first.
| GI Alliance | Sun City, Arizona, United States | Recruiting |
| GastroSb Weight Loss Clinic | Chula Vista, California, United States | Recruiting |
| Southern California Research Centers | Coronado, California, United States | Recruiting |
| VVCRD Research | Garden Grove, California, United States | Recruiting |
| UC San Diego Health System | La Jolla, California, United States | Recruiting |
| Gastro Care Institute | Lancaster, California, United States | Recruiting |
| Om Research LLC | Lancaster, California, United States | Recruiting |
| United Medical Doctors | Murrieta, California, United States | Withdrawn |
| University of California, Davis | Sacramento, California, United States | Recruiting |
| University of California San Francisco | San Francisco, California, United States | Recruiting |
| Amicis Research Center | Valencia, California, United States | Withdrawn |
| Luna Research | Coral Gables, Florida, United States | Recruiting |
+ 117 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06029972